Cargando…

Spontaneous Remission in a Patient With Acute Myeloid Leukemia Leading to Undetectable Minimal Residual Disease

Although rare, spontaneous remission (SR) of acute myeloid leukemia (AML) has been reported in the literature, the underlying mechanisms driving remission remain unknown. However, it is most commonly associated with a preceding severe infection. We present a case of a 40-year-old man with no past me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Helbig, Daniel, Quesada, Andres E., Xiao, Wenbin, Roshal, Mikhail, Tallman, Martin S., Knorr, David A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elmer Press 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188378/ https://www.ncbi.nlm.nih.gov/pubmed/32362981 http://dx.doi.org/10.14740/jh606

Ejemplares similares

Spontaneous hematological remission of acute myeloid leukemia
por: Kaźmierczak, Maciej, et al.
Publicado: (2014)

Spontaneous remission of acute myeloid leukemia with NF1 alteration
por: Bradley, Terrence, et al.
Publicado: (2020)

Spontaneous Remission of Acute Myeloid Leukemia: A Case Report
por: Martínez-Díez, Yolanda, et al.
Publicado: (2022)

Chasing quality remission in acute myeloid leukemia: intensity of induction and residual disease
por: Ofran, Yishai
Publicado: (2023)

Angiogenesis and Minimal Residual Disease in Patients with Acute Myeloid Leukemia
por: Nematollahi, Pardis, et al.
Publicado: (2020)

Molecular Minimal Residual Disease Detection in Acute Myeloid Leukemia
por: Vonk, Christian M., et al.
Publicado: (2021)

Spontaneous Complete Remission in a Patient with Acute Myeloid Leukemia and Severe Sepsis
por: Mozafari, Rambod, et al.
Publicado: (2017)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely
por: Ohyashiki, Junko H, et al.
Publicado: (2014)

Prognostic value of platelet recovery degree before and after achieving minimal residual disease negative complete remission in acute myeloid leukemia patients
por: Wang, Yang, et al.
Publicado: (2020)

Spontaneous Remission in a Patient with Chronic Myeloid Leukemia: A Case Report
por: Alshurafa, Awni, et al.
Publicado: (2023)

Repeated spontaneous remission of acute myeloid leukemia in response to various infections: a case report
por: Imataki, Osamu, et al.
Publicado: (2023)

Evaluation of Minimal Residual Disease in Acute Myeloid Leukemia with NPM1 Marker
por: Alizad Ghandforoush, Nasrin, et al.
Publicado: (2016)

Minimal Residual Disease in Acute Myeloid Leukemia: Still a Work in Progress?
por: Mosna, Federico, et al.
Publicado: (2017)

Monitoring Minimal Residual Disease in RUNX1-Mutated Acute Myeloid Leukemia
por: Nachmias, Boaz, et al.
Publicado: (2022)

Acute Myeloid Leukemia Stem Cells in Minimal/Measurable Residual Disease Detection
por: Srinivasan Rajsri, Kritika, et al.
Publicado: (2023)

Clinical Significance of Minimal Residual Disease at the End of Remission Induction Therapy in Childhood Acute Lymphoblastic Leukemia
por: Jovanovska, Aleksandra, et al.
Publicado: (2019)

Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia
por: Buccisano, Francesco, et al.
Publicado: (2018)

Next-generation sequencing in the diagnosis and minimal residual disease assessment of acute myeloid leukemia
por: Levine, Ross L., et al.
Publicado: (2019)

Precision and prognostic value of clone-specific minimal residual disease in acute myeloid leukemia
por: Hirsch, Pierre, et al.
Publicado: (2017)

Minimal Residual Disease Diagnostics and Chimerism in the Post-Transplant Period in Acute Myeloid Leukemia
por: Bacher, Ulrike, et al.
Publicado: (2011)

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia
por: Xiao, Wenbin, et al.
Publicado: (2019)

Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to the age of 60 years with Philadelphia chromosome-negative acute lymphoblastic leukemia
por: Geyer, Mark B., et al.
Publicado: (2020)

Dynamic assessment of measurable residual disease in favorable-risk acute myeloid leukemia in first remission, treatment, and outcomes
por: Yu, Sijian, et al.
Publicado: (2021)

Monitoring of Minimal Residual Disease (MRD) in Chronic Myeloid Leukemia: Recent Advances
por: Cumbo, Cosimo, et al.
Publicado: (2020)

Minimal Residual Disease in Acute Myeloid Leukemia of Adults: Determination, Prognostic Impact and Clinical Applications
por: Del Principe, Maria Ilaria, et al.
Publicado: (2016)

Multiplex accurate sensitive quantitation (MASQ) with application to minimal residual disease in acute myeloid leukemia
por: Moffitt, Andrea B, et al.
Publicado: (2020)

UMAP Based Anomaly Detection for Minimal Residual Disease Quantification within Acute Myeloid Leukemia
por: Weijler, Lisa, et al.
Publicado: (2022)

Clinical impact of minimal residual disease in blood and bone marrow of children with acute myeloid leukemia
por: Karol, Seth E., et al.
Publicado: (2023)

Association Between Measurable Residual Disease in Patients With Intermediate-Risk Acute Myeloid Leukemia and First Remission, Treatment, and Outcomes
por: Yu, Sijian, et al.
Publicado: (2021)

Minimal Residual Disease as a Predictive Factor for Relapse after Allogeneic Hematopoietic Stem Cell Transplant in Adult Patients with Acute Myeloid Leukemia in First and Second Complete Remission
por: Grubovikj, Rada M., et al.
Publicado: (2012)

Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT
por: Gilleece, Maria H., et al.
Publicado: (2021)

Defining consensus leukemia-associated immunophenotypes for detection of minimal residual disease in acute myeloid leukemia in a multicenter setting
por: Feller, N, et al.
Publicado: (2013)

Spontaneous remission of acute lymphoblastic leukemia: A case report
por: Höres, Timm, et al.
Publicado: (2018)

Age and remission induction therapy for acute myeloid leukemia: An analysis of data from the Korean acute myeloid leukemia registry
por: Yoo, Kwai Han, et al.
Publicado: (2021)

Detection of minimal residual disease in NPM1-mutated acute myeloid leukemia by next-generation sequencing
por: Salipante, Stephen J., et al.
Publicado: (2014)

A novel deep targeted sequencing method for minimal residual disease monitoring in acute myeloid leukemia
por: Onecha, Esther, et al.
Publicado: (2019)

Automated analysis of acute myeloid leukemia minimal residual disease using a support vector machine
por: Ni, Wanmao, et al.
Publicado: (2016)

The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients
por: Salehzadeh, Serena, et al.
Publicado: (2019)

The impact of the combination of KIT mutation and minimal residual disease on outcome in t(8;21) acute myeloid leukemia
por: Qin, Ya-Zhen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9rtnep8mahterj1qu4fc0ar31f